GlassScriptPhysician profile
Kausar Shamim
NPI 1053404749
$2,351.41
in general payments reported to CMS, 2019-2025
14 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $143 · 2021: $209 · 2022: $596 · 2023: $424 · 2024: $559 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $649.12 | 2019-2025 | Aristada, Lybalvi |
| Melinta Therapeutics, LLC | $377.82 | 2021-2024 | Orbactiv, Kimyrsa, Vabomere |
| Teva Pharmaceuticals USA, INC. | $326.66 | 2020-2024 | Uzedy |
| Shionogi INC | $272.05 | 2022-2024 | Fetroja |
| Otsuka America Pharmaceutical, INC. | $131.67 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $125.65 | 2023-2024 | Xarelto, Invega Sustenna, Invega Trinza |
| Gilead Sciences, INC. | $108.54 | 2023 | |
| La Jolla Pharmaceutical Company | $102.71 | 2023 | Xerava |
| E.R. Squibb & Sons, L.L.C. | $91.30 | 2025 | Cobenfy |
| Pfizer INC. | $53.32 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $47.59 | 2020 | |
| Lundbeck LLC | $24.81 | 2025 | Abilify Maintena |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kausar Shamim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.